NewsEarningsWanbury Limited Reports Strong Q2 FY26 Performance with 20% EBITDA Growth and 89% PAT SurgeWanbury Limited Reports Strong Q2 FY26 Performance with 20% EBITDA Growth and 89% PAT Surge
Wanbury Limited announced impressive Q2 FY26 results, with EBITDA growing 20% to ₹26.00 crore and PAT surging 89% to ₹15.20 crore year-over-year. The company's formulations business turned EBITDA positive, while the API business maintained strong performance. Wanbury also launched a new iron supplement brand, C-red, and allotted 15,000 equity shares under its ESOP 2016 plan. Additionally, the company issued 20,00,000 equity shares upon warrant conversion, increasing its paid-up share capital.
*this image is generated using AI for illustrative purposes only.
Wanbury Limited , a prominent player in the pharmaceutical sector, has announced its financial results for the second quarter of FY26, showcasing a robust performance and strategic corporate actions.
Financial Highlights
Wanbury reported significant growth in its quarterly results:
| Metric | Growth | Value |
|---|---|---|
| EBITDA | 20% | 26.00 |
| EBITDA Margin | - | 16.20% |
| Profit After Tax (PAT) | 89% | 15.20 |
The company achieved an EBITDA of ₹26.00 crore (16.20% margin) in Q2 FY26 compared to ₹21.60 crore (13.30% margin) in Q2 FY25, marking 20% growth. This performance indicates a strong financial position and operational efficiency, driven by enhanced product yields and procurement efficiencies.
Wanbury's PAT surged 89% to ₹15.20 crore from ₹8.00 crore year-over-year, demonstrating significant bottom-line improvement.
Business Segment Performance
- The formulations business turned EBITDA positive
- The API business maintained strong performance
Strategic Initiatives
The company highlighted successful digital transformation efforts and expressed commitment to sustainable growth through new product launches. Notably, Wanbury successfully launched a new iron supplement brand called C-red.
Employee Stock Option Plan
Wanbury's Board approved the allotment of 15,000 equity shares under its Employee Stock Option Plan 2016 (WANBURY ESOP 2016). These shares, with a face value of ₹10 each, were issued at par to an eligible employee who exercised vested options.
Impact on Share Capital
Following this allotment, Wanbury's paid-up share capital has increased to ₹34,89,19,980, divided into 3,48,91,998 fully paid-up equity shares of ₹10 each. This represents an increase from the previous share capital of ₹34,87,69,980.
Corporate Actions
During the quarter, the company also allotted 20,00,000 equity shares upon the exercise of conversion options attached to warrants. This resulted in an increase of ₹200.00 lakhs in the paid-up share capital and ₹2,200.00 lakhs in the Securities Premium account.
Management Commentary
The management expressed satisfaction with the company's performance, highlighting the success of their business model and the dedication of their team. The allotment of employee stock options underscores their commitment to aligning the workforce with the company's long-term success.
Future Outlook
Wanbury continues to focus on its core pharmaceutical segment, leveraging its US FDA-approved manufacturing facilities in Tanuku (Andhra Pradesh) and Patalganga (Maharashtra) to drive growth. The company's commitment to sustainable growth through new product launches, as evidenced by the introduction of C-red, suggests a positive outlook for future quarters.
Historical Stock Returns for Wanbury
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.63% | -3.25% | -7.64% | -17.83% | -7.57% | +580.08% |
20
